Aveo Pharmaceuticals Next Hit ?

wie sie gestiegen ist wieder runter....
wenn sie bei 1,00$ ist steige ich mal probehalber mit ein.  

bei mir jucket jetzt schon in den Fingern ;)  

mal sehen.....  

sieht tatsächlich so aus, als würde sich ein Boden um die 1,20 EUR bilden. Die Marke wurde ja auch damals im Forbes Artikel genannt.
(http://www.forbes.com/sites/greatspeculations/...lionaire-believers/)

Ursache für den Rücksetzer war keine News von AVEO, oder habe ich da was verpasst?

Im mom sehe ich den Rücksetzer nämlich als Ergebnis von Gewinnmitnahmen, Abstrafung des gesamten Biotech-Sektors und dem damit eingehenden negativen Verlauf des NBI.  

Mal sehen, ob der Lift eingeschalten wird..  

bin gestern mal rein mit einer kleinen "Zocker-Position". Wir brauchen Volumen. NBI sieht gut aus, sollte sich das ändern wird es auch wieder schwieriger für aveo.  

was für einen RSI haben wir denn jetzt gerade? bzw. kann mir einer sagen wo ich nach solchen infos kucken kann. bzw wie ich ihn mir selber ausrechne. danke euch

beobachte diese Aktie schon länger und jetzt nach dem abverkauf wäre das evtl jetzt wieder ein guter einstieg  

Real-Time etc. kannst du alles auf yahoo und nasdaq gucken. Eine besser (kostenlose) Seite gibts da meines Wissens nicht für AVEO. Wobei im mom ist es langweilig. Alle sind wieder bei ARIAD. ;)

Aktuelles Bid/Ask Orderbuch hier:
http://www.batstrading.com/bzx/book/AVEO/

Noch ganz nett zur Chartanalyse:
https://www.tradingview.com/e/?symbol=AVEO

Irgendwo habe ich außerdem gelesen, dass Anfang August die Zahlen kommen  

Könnte man gut einsteigen jetzt ;)  

http://shortanalytics.com/getshortchart.php?tsymbol=aveo  

Earnings announcement* for AVEO: Aug 06, 2014

AVEO Pharmaceuticals, Inc. is expected* to report earnings on 08/06/2014 after market close. The report will be for the fiscal Quarter ending Jun 2014. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.38. The reported EPS for the same quarter last year was $-0.62.

Read more: http://www.nasdaq.com/earnings/report/aveo#ixzz39RZ2tzJF  

interessant werden, gespannt auf die Zahlen.
Und sehe ich richtig das BlackRock ihre Anteile am 8.7.2014 auf fast das doppelte erhöht
hat?

Aggregate amount beneficially owned by each reporting person 2352120 (sec filling vom 10.7)
Der Schlusskurs an diesem Tag $1.49
 

Mit über 220000 stk zum Schlusskurs..sollte  ein gute Zeichen für Montag sein...oder üblich bei aveo...verfolge nur ab und zu die schlusskurse..?!?
Vg
Andreas  

Saul Markman, Peeling The Onion (5 clicks)
Profile| Send Message|
Follow (12 followers)  
AVEO Oncology: A New Platform To Create Oncology Drugs
Sep. 14, 2014 7:35 PM ET  |  5 comments  |  About: AVEO Pharmaceuticals, Inc. (AVEO)

[Originally published 9/1/2014]

AVEO Oncology (NASDAQ:AVEO) is a Cambridge Mass. based company, founded 10 years ago and traded on NASDAQ. AVEO has created new and interesting oncology treatments, mostly antibodies. An interesting pipeline has been developed.

What is unique and interesting about this company, is that they have developed a platform on which to build an ever expanding pipeline. Their Human Response Platform (discussed below) is a new and patented methodology to identify potential targets for cancer treatments.
AVEO Oncology: Rating the Company

AVEO is very unique in its approach to developing oncologic products. They are not totally unique in the sense that many competitors are developing antibodies for targeted cancer therapy. The approach they are using can be used against many types of cancer rendering their market size enormous.

AVEO is still quite early in human trials for most of their pipeline.
AVEO Oncology: Human Response Platform

The Human Response Platform (HRP) is a new type of model intended to identify oncologic drug candidates. Models developed under the HRP should increase the success rate of developing anti tumor drugs.

The intention is to identify and test target genes that drive tumor growth, to develop drugs that block these targets and ultimately to identify patients most likely to respond to these drugs.

This is done through proprietary models, using new techniques discovered by AVEO’s scientists.

AVEO’s HRP: How it Works

AVEO was founded by two high ranking MDs from MD Anderson Cancer Center in Texas and a Harvard PhD. Better mouse models to drive the design and patient selection of clinical trials were, and are, at the core of AVEO’s work.

Here is a brief, simplified version of how the process works:

   Incorporate into stem cells, human cancer lesions that have human oncogenes (cancer causing genes).
   Put the stem cells into mice.
   Develop a population of murine (mouse) tumors.
   Gain insight about tumor characteristics and apply them to humans.

In essence you have designer tumors (because you’ve picked the oncogene) growing in mice. These are human tumors. Because the tumors are human in origin, they give better information about how to treat the particular tumor than you could get using mouse tumors. This is theoretically a better model than any test tube model.

The HRP platform allows insight into tumor biology and into the hows and whys of drug response and/ or resistance. Models such as these can be developed for virtually any tumor that has an oncogene that can be isolated.
AVEO’s Human in Mouse Model

The Human in Mouse Model (HIM) is another proprietary model developed at AVEO. Normal human breast tissue, usually taken from breast reduction surgery, is modified with oncogenes so that it will likely develop cancer. The modified tissue is injected into specially engineered mice. The injected cells become normal breast tissue and migrate to join the mouse’s breast tissue. The cells rapidly develop breast cancer in the mouse’s breast.

This allows the same kind of insights as the HRP platform.
AVEO’s Pipeline of Targeted Therapy

The importance of these models is to develop targeted therapy; that is, therapy designed for people who have tumors with the same oncogene as the tumors in the mouse. If you can prove that an anticancer treatment works on the human tumor in the mouse, then there’s a good chance it will work on a genetically identical tumor in patients.

AVEO currently has four drugs in the pipeline designed with that concept in mind. They have several others in development. The concept can be applied to many tumors. If you can find a target and if you can build an antibody to the target, then you can attack the tumor.

Below, I will discuss the various drugs in the pipeline.
AVEO’s AV-203

Recent evidence suggests that a molecule named Erb B3 is important in tumor formation and growth. When Erb B3 is activated it promotes new tumors, tumor growth and resistance to chemotherapy. For activation it binds to an Erb B3 receptor also known as Human Epidermal Growth Factor Receptor 3 (HER3), a receptor closely related to HER1 and HER2 which are targeted in certain breast cancer treatments. The Erb B3 receptor is expressed in many tumors.

AV-203 is an antibody against Erb-B3. It inhibits the ability of Erb B3 to send signals to the tumor to grow, or to form drug resistance. If the antibody works as planned, tumor growth is severely inhibited. AV-203 seems to work whether or not the Erb-B3 is attached to its receptor.

In pre-clinical studies AV-203 showed activity in models of many cancers including breast, head and neck, lung, pancreatic and ovarian. A Phase 1 study has delineated maximal acceptable dose for a good toxicity profile.

A biomarker has been developed and validated for patient selection. Patients whose tumors express this marker are more likely to respond to this therapy.

It has also been established that for any given cancer, an overexpression of Erb B3 confers a poor prognosis, much like HER1 and HER 2 in breast cancer.
AVEO’s Ficlatuzimab

Ficlatuzimab, which was developed as AV-299, is an antibody inhibitory to Hepatocyte Growth Factor (HGF). Ficlatuzimab binds with great affinity and great specificity to a small part (ligand) of the HGF molecule.

HGF is important in embryonic cell growth. Pathologically it plays a part in tumor genesis, rapid cell division and angiogenesis. Angiogenesis is an important mechanism to support tumor growth. It’s the development of new blood vessels to provide nutrition to rapidly growing tumors. HGF has to interact with its receptor (C-Met) to be effective. Ficlatuzimab inhibits the signalling function of the HGF/C-Met compound. Tumor growth is inhibited directly and by decreasing new vessel growth. Metastases are also inhibited.

Ficlatuzimab is being tested alone and in conjunction with an anti cancer drug called erlotinib. Erlotinib is one of a new class of anti cancer drugs that work by inhibiting tyrosine kinases. In particular it inhibits the Epidermal Growth Factor Receptor (EGFR). EGFR and HGF are often overexpressed in the same cancers , so the combination therapy is logical.

AVEO is also involved in an analysis of Veristocet which is a patented protein marker in the serum, believed to be predictive in the survival of patients with non small cell lung cancer treated with drugs such as erlotinib. It makes sense that if this marker predicts a poor outcome in patients treated with a tyrosine kinase inhibitor, that Ficlatuzimab be added to the regimen. An exploratory analysis is being done to predict benefits of adding Ficlatuzimab based on a Phase 2 study of first line treatment of non small cell lung cancer with tyrosine kinase inhibitors.

The HGF/C Met complex is overexpressed in colorectal, gastric, head and neck, breast, lung and prostate cancer amongst solid malignancies as well as hematologic malignancies.
AVEO’s Tivozanib

There are three Vascular Endothelial Growth Factor Receptors (VEGFRs). All 3 are blocked by Tivozanib (an anti VEGFR antibody). On the VEGF molecule there are five identified important ligands (ligands are small molecules that bind to larger molecules). These 5 ligands bind to the three VEGFRs with different but overlapping binding profiles. Block the 3 receptors and you neutralize all 5 ligands.

VEGFR 1 is crucial for new vessel growth in cancers and for the survival of the endothelial cells that line blood vessels. VEGFR 2 is not as well understood but appears to be important for the growth and appropriate migration of endothelial cells. VEGFR 3 is important in the formation of connecting networks of vessels.

Block all three VEGFRs as Tivozanib does and new vessels are not formed to promote tumor growth and nutrition. It’s analogous to choking off the root system of a growing plant.

AVEO was collaborating with Astellas to promote this product but as of August 2014, the rights revert to AVEO who will explore other partnerships.

AVEO’s AV-380

AV-380 is a first in class inhibitor of GDF-15. I will not go into the many functions of this member of the growth factor family.

Of importance to cancer patients is that it seems to mediate cachexia. Cachexia, sometimes called wasting syndrome, is a syndrome consisting of weight loss, muscle atrophy, loss of appetite, weakness and fatigue. Cachexia is present in over half of cancer patients. A myriad of other diseases including (but not limited to) AIDS, Congestive Heart Failure, Tuberculosis, Chronic Obstructive Lung Disease, Renal Failure and Multiple Sclerosis also have cachexia as a feature.

AVEO is attempting to rapidly show proof of clinical activity of AV-380 in cachexia with an eye towards human trials in about a year.
Other Molecules Developed by Human Response Platform

A limitless number of other targets can be identified by HRP. The next targets for antibodies have been identified in this manner.

Fibroblast Growth Factors and their receptors are an important signalling network in the regulation of cell growth, differentiation and survival. Often deregulated in cancer, they confer rapid growth and increased survival to tumour cells. They stimulate new vessel formation as well. There are 4 FGF receptors and AVEO is developing antibodies to FGFR 2 and FGFR 3.

Similarly the NOTCH signalling pathway is important in the genesis and growth of tumours. AVEO is developing antibodies against 2 of the 4 Notch receptors.
AVEO: Where are They Going?

I think AVEO is an exciting company. The HRP platform has been designed by an extremely strong scientific group. Its claims of being a better way to assess appropriate anti tumor targets appear to be valid.

Using the HRP platform they have developed a strong pipeline. The exciting part is that using the same technology they should be able to create a vast pipeline.

The market size is enormous as it encompasses many cancers. If AV-380 can really modulate cachexia, then we are talking about a market of unprecedented size, encompassing not only cancer patients but also patients with common diseases such as CHF, COPD, MS and renal failure.

A word of warning: Many antibodies are being produced and marketed, some very successfully. However 2014 has been marked by antibodies that looked great in pre-clinical studies, only to fail Phase 2 Trials. AVEO seems poised for success but as with any new product, success will hinge on Phase 2 clinicals.

Disclosure: The author has no positions in any of the stocks mentioned. The author wrote this article themselves and is not receiving compensation for it.  

sind Präsentationen der Produktkandidaten....

Clinical Data on AVEO Oncology’s Ficlatuzumab and Tivozanib to Be Presented at the ESMO 2014 Congress
By Business Wire,  September 17, 2014, 06:00:00 AM EDT
Vote up
A A A


CAMBRIDGE, Mass.--(BUSINESS WIRE)-- AVEO Oncology (NASDAQ:AVEO) today announced that clinical data on ficlatuzumab, the Company's hepatocyte growth factor (HGF) inhibitory antibody, as well as tivozanib, the Company's inhibitor of vascular endothelial growth factor (VEGF) 1, 2, and 3 receptors, will be presented at the European Society of Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, September 26 - September 30, 2014.

"We believe there is meaningful therapeutic value in our clinical-stage product candidates, value we look forward to realizing through partnerships," said Tuan Ha-Ngoc, president and chief executive officer of AVEO. "The foundation of our partnership with Biodesix, for the development and commercialization of ficlatuzumab, is in the promising results from an analysis of serum proteomic based subgroups that will be presented at this year's ESMO congress. We also believe that tivozanib, for which we have recently regained rights, continues to show potential as an oral VEGF inhibitor."

The schedule for the ficlatuzumab and tivozanib poster presentations at ESMO is as follows:


Date and Time: Sunday, September 28, 2014 at 12:45 p.m. (CEST)

Session: Biomarkers Poster Display

Title: Efficacy analysis of gefitinib +/- ficlatuzumab in serum proteomic based subgroups of patients with previously untreated lung adenocarcinoma

Poster Number: 205P

Room: Poster Area

Presenter: Tony Mok, MD


Date and Time: Sunday, September 28, 2014 at 12:45 p.m. (CEST)

Session: Biomarkers Poster Display

Title: Phase 2 clinical evaluation of preclinically defined biomarkers for vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) tivozanib in renal cell carcinoma (RCC)

Poster Number: 233P

Room: Poster Area

Presenter: Thomas Hutson, DO, PharmD


Date and Time: Monday, September 29, 2014 at 12:45 p.m. (CEST)

Session: GI-CRC Poster Display

Title: BATON-CRC: a phase 2 randomized trial comparing tivozanib (tivo) + mFOLFOX6 with bevacizumab (bev) + mFOLFOX6 in stage IV metastatic colorectal cancer (mCRC)

Poster Number: 533P

Room: Poster Area

Presenter: Al Benson III, MD


About Ficlatuzumab

Ficlatuzumab is a humanized IgG1κ antibody that binds to the HGF ligand with high affinity and specificity to inhibit the biological activities of the HGF/c-Met pathway. Studies have demonstrated that ficlatuzumab is well tolerated as a single agent as well as in combination with EGFR TKIs. In April 2014, AVEO and Biodesix, Inc. entered into a worldwide agreement to develop and commercialize ficlatuzumab with a Biodesix® companion diagnostic test.

About Tivozanib

Tivozanib is an oral, once-daily, investigational vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). It is a potent, selective and long half-life inhibitor of all three VEGF receptors and is designed to optimize VEGF blockade while minimizing off-target toxicities, potentially resulting in improved efficacy and minimal dose modifications. Tivozanib has been evaluated in several tumors types, including renal cell, colorectal and breast cancers.

About AVEO

AVEO Oncology (NASDAQ:AVEO) is a biopharmaceutical company committed to discovering and developing targeted therapies designed to provide substantial impact in the lives of people with cancer by addressing unmet medical needs. AVEO's proprietary Human Response Platform™ provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. For more information, please visit the company's website at www.aveooncology.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of AVEO within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "could," "should," "seek," or the negative of these terms or other similar expressions, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about AVEO's plans to leverage its partners' resources for its clinical stage product candidates; the ability of AVEO's partnership with Biodesix to identify patients who may gain benefit from ficlatuzumab; and the potential of tivozanib as an oral VEGF inhibitor . Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that AVEO makes due to a number of important factors, including risks relating to: AVEO's ability to execute on its business strategy and enter into and maintain new strategic partnerships and collaboration agreements; AVEO's ability to successfully enroll and complete clinical trials and preclinical studies of its product candidates; AVEO's ability to demonstrate to the satisfaction of the FDA, or equivalent foreign regulatory agencies, the safety, efficacy and clinically meaningful benefit of its product candidates; AVEO's ability to achieve and maintain compliance with all regulatory requirements applicable to its product candidates; AVEO's ability to obtain and maintain adequate protection for intellectual property rights relating to its product candidates and technologies; developments and expenses related to AVEO's ongoing shareholder litigation and SEC inquiry; AVEO's ability to raise the substantial additional funds required to achieve its goals; adverse general economic and industry conditions; competitive factors; and those risks discussed in the section titled "Risk Factors" included in AVEO's most recent Quarterly Report on Form 10-Q and in its other filings with the SEC. The forward-looking statements in this press release represent AVEO's views as of the date of this press release. AVEO anticipates that subsequent events and developments will cause its views to change. However, while AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO's views as of any date subsequent to the date of this press release.

Source: AVEO Oncology


This article appears in: News Headlines

Referenced Stocks: AVEO

 

die Aktivitäten von AVEO Pharmaceuticals im Bereich der Cachexia-Krebsforschung.
Cachexia ist Muskelschwäche, eine schwerwiegende Komplikation im Spätstadium von Krebs, gegen die es meines Wissens kein zugelassenes Medikament am Markt gibt.
AVEO hat einen monklonalen Antikörper separiert, GDF 115, der hier eingesetzt werden soll.
Die Produktkandidaten Ficlatuzumab und Tivozanib werden diesen Monat in Madrid präsentiert ( beide Kandidaten sind tief gefallen und werden neu aufgebaut) , doch GDF 115 in Montreal, Kanada.

Es gibt gar keine Presseerklärung von AVEO darüber, doch ich habe lange recherchiert.

Cachexia ist so ein schwerwiegendes medizinisches Problem, dass es eigens zu diesem Thema internationale Konferenzen gibt:

http://www.cvent.com/events/...-60a9893a0ded4e64862953fef956f3b9.aspx

Ich habe die dreitägige Tagesordnung studiert und herausgelesen, dass neben allen Wissenschaftlern, auch die Wissenschaftlerin Leona Lerner von AVEO am letzten Tag spricht.

3:45-4:15 pm Targeting GDF15 with the inhibitory antibody AV-380 for the treatment of Cancer Cachexia
Lorena Lerner, PhD
Director
AVEO Oncology Inc.
Cambridge, Massachusetts, USA

Von dieser Konferenz verspreche ich mir, dass AVEO Pharmaceuticals einen grossen Pharmapartner findet und der Kurs von gestern 1,27 Dollar sich verdoppelt in 2015.
Mit dieser Perspektive habe ich 20.000 Aktien gekauft, allerdings in EURO, ca. 1 Euro das Stück.
Ich hoffe, dass meine umfangreiche Recherchearbeit mit einem "Glückstreffer" belohnt wird.

Schönes Wochenende.  

 

ist heute rausgekommen. Etwas spät, aber jetzt offiziell. Tue Gutes und sprich darüber.
Diese Konferenz könnte ein wichtiger Schritt sein, um einen potentiellen FinanzPartner
aus der Pharmabranche zu finden. Nun und dann verdoppelt sich der Kurs, exemplarisch war dieses Jahr dafür ACHN oder AVNR.
Gute Wissenschaftler hat AVEO, gute Investoren noch nicht, der Kurs ist dramatisch gefallen die letzten 4 Jahre. Ich setze auf den Turnaround...

Wer die Presseerklärung lesen möchte, heute 26.09.14, auf der AVEO Homepage veröffentlicht.

http://www.aveooncology.com/  

Das könnte heute was geben.Aber denke das bis zum Start noch etwas runter geht.  

http://finance.yahoo.com/news/...ligibility-submission-113000625.html

ARNA hat gestern nach ähnlichen News 72% gemacht.  

zwischen 0,93 und 0,95 im Moment, also zwischen 13% und 16% plus derzeit. Ich halte so oder so, egal wie das heute ausgeht. Solche neuen News müssen sich auch erstmal rumsprechen.
Gestern hatten sie den CEO abgesägt bei AVEO und die Belegschaft nochmal verkleinert. Das sind eher schwer zu verdauende Nachrichten.
Die Firma ist einfach zu klein, um von FONDS gekauft werden zu dürfen, eine Marktkapitalisierung von schmalen 45 Millionen darf kein Fondsmanager kaufen, da müssen wir Klerinanleger ran. Sprung auf 0,97 und 16% aktuell...  

eher nicht.mal Gap sind was für klein Anleger. ;-)  

oszilliert der Kurs um 0,95, doch der Ausbruch will noch nicht gelingen, erst bei 1,15 schneidet der GD 38 den 200er.
Tivozanib soll jetzt der europäischen Arzneimittelbehörde vorgelegt werden,  nachdem das Medikament seinerzeit von der FDA abgelehnt wurde.
Wenn Tivozanib gegen das Nierenzellkarzinom in Europa angenommen wird geht der Kurs durch die Decke und verdoppelt sich an einem Tag auf 2 Dollar mit Ziel 7 Dollar in einem Jahr, das ist die Fantasie in der Aktie.
Deshalb halte ich seit September letzten Jahres. Zwischendurch war mir schon mulmig, nach Kaufkurs 1,04 sackt der Kurs im Dezember auf 0,61 runter, das war echt kein Vorweihnachtsgeschenk doch ich habe aus fundamentalen Gründen gehalten.
Im Februar möchte ich für meine Geduld belohnt werden.  

Eine Studie zu Tivozanib bewegt die Aktie 20% ins Plus. Wenn es bis zum Abend so bleibt, hat der GD38 endlich den 200SMA von unten durchkreuzt, das lang erhoffte Kaufsignal. Investoren interessiert doch technisch auch, ob der Kurs über dem SMA 200 notiert. Höhere Ziele sind offen...
Schönes Wochenende.

http://www.nasdaq.com/press-release/...s-and-biomarker-20150227-00161